Grove Biopharma has expanded its footprint at Trammell Crow Company’s (TCC) Fulton Labs campus in Chicago’s Fulton Market district.
The biotech startup signed a lease for a larger space within the 400,000-square-foot lab building at 400 N. Aberdeen Street. Grove Biopharma, which previously operated out of Portal Innovation’s Fulton Labs location, also announced the close of a $30 million Series A financing round.
“In the past, a company on this growth trajectory would have considered moving to one of the coasts, but both Portal and Fulton Labs have provided an environment where science startups can grow and thrive here in Chicago,” said Morgan Baer Blaska, Vice President with TCC Midwest.
Dan Lyne of CBRE represented TCC in the deal. Jonathan Metzl and Chip Evans of Cushman & Wakefield represented Grove Biopharma. The company joins a roster of tenants, including Portal Innovations, Mattiq, the Chan-Zuckerberg BioHub, the Chicagoland Climate Investment Alliance, P33, Rhaeos, and Illinois Tech.
The post Grove Biopharma Leases Larger Space at TCC’s Fulton Labs appeared first on Connect CRE.
